- Home
- CATX vs NTHI Comparison
CATX vs NTHI Comparison
Compare CATX & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- NTHI
- Stock Information
- Founded
- CATX 1983
- NTHI 2008
- Country
- CATX United States
- NTHI United States
- Employees
- CATX N/A
- NTHI N/A
- Industry
- CATX Medical/Dental Instruments
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- CATX Health Care
- NTHI Health Care
- Exchange
- CATX Nasdaq
- NTHI Nasdaq
- Market Cap
- CATX 239.0M
- NTHI 211.9M
- IPO Year
- CATX N/A
- NTHI N/A
- Fundamental
- Price
- CATX $2.73
- NTHI $9.67
- Analyst Decision
- CATX Strong Buy
- NTHI
- Analyst Count
- CATX 10
- NTHI 0
- Target Price
- CATX $12.30
- NTHI N/A
- AVG Volume (30 Days)
- CATX 1.7M
- NTHI 43.2K
- Earning Date
- CATX 11-10-2025
- NTHI 11-19-2025
- Dividend Yield
- CATX N/A
- NTHI N/A
- EPS Growth
- CATX N/A
- NTHI N/A
- EPS
- CATX N/A
- NTHI N/A
- Revenue
- CATX $1,235,000.00
- NTHI $59,990.00
- Revenue This Year
- CATX N/A
- NTHI N/A
- Revenue Next Year
- CATX N/A
- NTHI N/A
- P/E Ratio
- CATX N/A
- NTHI N/A
- Revenue Growth
- CATX N/A
- NTHI N/A
- 52 Week Low
- CATX $1.60
- NTHI $3.20
- 52 Week High
- CATX $12.90
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- CATX 35.35
- NTHI N/A
- Support Level
- CATX $2.85
- NTHI N/A
- Resistance Level
- CATX $3.15
- NTHI N/A
- Average True Range (ATR)
- CATX 0.47
- NTHI 0.00
- MACD
- CATX -0.17
- NTHI 0.00
- Stochastic Oscillator
- CATX 0.75
- NTHI 0.00
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).